Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico

We read with interest the articles by Sotgiu et al . [1] and Dalcolmo et al . [2], which initiated a debate on the suitability of the shorter regimen for multidrug-resistant (MDR) tuberculosis (TB) cases in different settings [2–6]. The shorter World Health Organization (WHO) regimen [7, 8] is composed of an initial phase of 4–6 months of kanamycin, moxifloxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid and ethambutol, followed by 5 months of moxifloxacin, clofazimine, pyrazinamide and ethambutol. Comparing phenotypic and genotypic results in Mexico: guidance for the adoption of the shorter MDR-TB regimen